Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Combo Products Review Transformation Begins

Executive Summary

Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.

Advertisement

Related Content

PDUFA First: Fees To Support Device Center Staff
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'
Califf Lowering FDA Drawbridge To Work With External Expertise
Califf Supports Combo Products Pathway At Confirmation Hearing
Will Combination Products Join The User Fee Family?
FDA/Generic Communications Plan Restoring Best Of Past Practices
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
For Combination Product Development, Industry Says Talk Is Cheap

Topics

Advertisement
UsernamePublicRestriction

Register

PS118998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel